You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
榮昌生物(688331.SH):泰它西普治療原發性乾燥綜合徵Ⅲ期臨牀研究達到主要研究終點

格隆匯8月13日丨榮昌生物(688331.SH)公佈,自主研發的BLyS/APRIL雙靶點融合蛋白創新藥泰它西普(RC18,商品名:泰愛®)用於治療原發性乾燥綜合徵(pSS)的Ⅲ期臨牀研究,達到方案設計的臨牀試驗主要研究終點。研究表明,自身反應性的B細胞過度活化是乾燥綜合徵發病的重要病理基礎。泰它西普是由榮昌生物自主研發的重組B淋巴細胞刺激因子(BLyS)/增殖誘導配體(APRIL)雙靶點融合蛋白,通過同時抑制BLyS和APRIL與B細胞表面受體結合,阻止B細胞異常分化和成熟,有效減輕機體的病理性免疫反應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account